Author

C. J. Logothetis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 5 Research Focus:cell type annotation· 4 Organism:mouse· 4 Assay:proteomics· 4 Research Focus:differential expression· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2

Frequent Co-Authors

S.-H. Lin· 4 shared G. Wang· 3 shared J. H. Song· 3 shared M. Zhu· 3 shared P. Troncoso· 3 shared A. Aparicio· 2 shared A. K. Jain· 2 shared C. S. L. Mak· 2 shared

Activity by Year

2021-2022 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S.-H. Lin

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX)

N. Anselmino, E. Labanca, X. Song, J. Yang, P. D. Shepherd, J. Dong, R. Kundra, N. Schultz, J. Zhang, J. C. Araujo, A. M. Aparicio, S. K. Subudhi, P. G. Corn, L. L. Pisters, J. F. Ward, , N. M. Navone

The paper characterizes the genomic and transcriptomic landscape of MDA PCa PDX models and develops an organoid platform to study prostate cancer heterogeneity and resistance.

bioRxiv · Jul 21, 2022 · PreprintCancer Biology

KDM4A promotes the progression of neuroendocrine prostate cancer

C. S. L. Mak, M. Zhu, X. Liang, F. Wang, F. Yuan, A. G. Hoang, X. Song, P. Shepherd, D. Liang, J. Suh, B. Pradhan, J. Park, M. Zhang, E. Metzger, R. Schule, , G. Wang

This study identifies KDM4A as a key driver of neuroendocrine prostate cancer progression and shows that targeting KDM4A inhibits tumor growth in preclinical models.

bioRxiv · May 14, 2022 · PreprintCancer Biology

Activation of retinoic acid receptor reduces metastatic prostate cancer bone lesions through blocking endothelial-to-osteoblast transition

G. Yu, P. G. Corn, P. Shen, J. H. Song, Y.-C. Lee, S.-C. Lin, J. Pan, S. K. Agarwal, T. Panaretakis, M. Pacifici, C. J. Logothetis, L.-y. Yu-Lee, S.-H. Lin

bioRxiv · Dec 22, 2021Cancer Biology

Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition

S.-H. Lin, Y.-C. Lee, S.-C. Lin, G. Yu, M. Zhu, J. H. Song, K. Rivera, D. J. Pappin, C. J. Logothetis, T. Panaretakis, G. Wang, L.-y. Yu-Lee

This study shows that prostate tumor-induced stromal reprogramming produces Tenascin C, which promotes metastasis by inhibiting YAP/TAZ through 5{beta}1 integrin.

bioRxiv · Nov 8, 2021Cancer Biology

H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies

C. Terranova, M. Maitituoheti, A. T. Raman, M. Tang, N. E. Anvar, A. K. Ghosh, S. B. Amin, J. Schulz, E. Orouji, F. Giancotti, P. Troncoso, C. J. Logothetis, T. Thompson, K. Rai

The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.

bioRxiv · Sep 2, 2021 · PreprintCancer Biology

Measuring the metabolic evolution of glioblastoma throughout tumor development, regression, and recurrence with hyperpolarized magnetic resonance

T. C. Salzillo, V. Mawoneke, J. Weygand, A. Shetty, J. Gumin, N. M. Zacharias Millward, S. T. Gammon, D. Piwnica-Worms, G. N. Fuller, C. J. Logothetis, F. F. Lang, P. K. Bhattacharya

This study uses hyperpolarized MRI to track metabolic changes in glioblastoma across development, regression, and recurrence, showing its superior sensitivity compared to conventional MRI.

bioRxiv · Jun 10, 2021Biophysics

Transcriptional Inactivation of TP53 and the BMP Pathway Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

H. Han, Y. Wang, J. N. Curto, S. Gurrapu, S. Laudato, A. Rumandla, G. Chakraborty, X. Wang, H. Chen, Y. Jiang, D. Kumar, E. G. Caggiano, B. Zhang, Y. Ji, S. N. Maity, , F. G. Giancotti

The paper identifies a novel subtype of therapy-induced prostate cancer cells with hybrid E/M and stem-like traits, showing their dependency on HER2/3 signaling and resistance to AR inhibition.

bioRxiv · Apr 14, 2021 · PreprintCancer Biology

P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis

M. Zhu, R. Peng, X. Liang, Z. Lan, M. Tang, P. Hou, J. H. Song, C. S. L. Mak, J. Park, S.-e. Zheng, A. Huang, X. Ma, R. Chen, Q. Chang, C. J. Logothetis, , G. Wang

This study identifies P4HA2-dependent prolyl hydroxylation of YAP1 as a suppressor of prostate cancer cell migration, invasion, and metastasis.

bioRxiv · Jan 24, 2021Cancer Biology